An update on the pathogenesis of cholesterol gallstone disease

A Di Ciaula, DQH Wang… - Current opinion in …, 2018 - journals.lww.com
An update on the pathogenesis of cholesterol gallstone disea... : Current Opinion in
Gastroenterology An update on the pathogenesis of cholesterol gallstone disease : Current …

[HTML][HTML] Recent advances in understanding and managing cholesterol gallstones

A Di Ciaula, P Portincasa - F1000Research, 2018 - ncbi.nlm.nih.gov
The high prevalence of cholesterol gallstones, the availability of new information about
pathogenesis, and the relevant health costs due to the management of cholelithiasis in both …

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

D Glintborg, M Andersen - European journal of endocrinology, 2017 - academic.oup.com
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition in
premenopausal women. The syndrome is characterized by hyperandrogenism, irregular …

Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention

A Di Ciaula, DQH Wang… - Expert review of …, 2019 - Taylor & Francis
Introduction: Cholesterol gallstone disease have relationships with various conditions linked
with insulin resistance, but also with heart disease, atherosclerosis, and cancer. These …

Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review

D Glintborg, M Andersen - Current Opinion in Obstetrics and …, 2017 - journals.lww.com
Medical comorbidity in polycystic ovary syndrome with specia... : Current Opinion in Obstetrics
and Gynecology Medical comorbidity in polycystic ovary syndrome with special focus on …

Metformin treatment prevents gallstone formation but mimics porcelain gallbladder in C57Bl/6 mice

MR Dorvash, MJ Khoshnood, H Saber… - European Journal of …, 2018 - Elsevier
Gallstone disease (GD) is highly correlated with metabolic syndrome and its related
illnesses including type II diabetes (DMII) and polycystic ovary syndrome (PCOS). While …

Medical treatment and comorbidity in polycystic ovary syndrome: an updated review

D Glintborg, M Andersen - Current Opinion in Endocrine and Metabolic …, 2020 - Elsevier
Polycystic ovary syndrome (PCOS) is defined by hyperandrogenism, irregular menses, and
polycystic ovaries when other etiologies are excluded. The risk of type 2 diabetes and …

GDF-15 as a therapeutic target of diabetic complications increases the risk of gallstone disease: Mendelian randomization and polygenic risk score analysis

L Yu, Y Zhou, L Wang, X Zhou, J Sun, J Xiao… - Frontiers in …, 2022 - frontiersin.org
Growth differentiation factor 15 (GDF-15) levels have been revealed as a robust biomarker
for metformin use. We conducted Mendelian randomization (MR) analysis to explore the …

Желчнокаменная болезнь как коморбидное синдрому поликистозных яичников заболевание

ЮБ Успенская, ИВ Кузнецова - Гинекология, 2015 - cyberleninka.ru
Синдром поликистозных яичников (СПКЯ) сложная междисциплинарная проблема в
связи с вовлечением в патогенез не только нарушений репродуктивной системы, но и …

Comorbidity, work ability, and disability retirement among women with polycystic ovary syndrome (PCOS): a population-based analysis in the Northern Finland Birth …

L Kujanpää - 2023 - oulurepo.oulu.fi
Polycystic ovary syndrome (PCOS), the most common yet underdiagnosed endocrine
disorder in women, affects 6–18% of the female population. Given that PCOS is associated …